As of 2025-10-22, the EV/EBITDA ratio of Y-mAbs Therapeutics, Inc (YMAB) is -18.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. YMAB's latest enterprise value is 391.24 mil USD. YMAB's TTM EBITDA according to its financial statements is -20.75 mil USD. Dividing these 2 quantities gives us the above YMAB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.7x - 14.8x | 14.3x |
| Forward P/E multiples | 27.4x - 48.3x | 44.7x |
| Fair Price | (12.49) - (6.78) | (13.47) |
| Upside | -245.1% - -178.7% | -256.4% |
| Date | EV/EBITDA |